Community Pharmacists Now Administering Long-Acting Injectable Antipsychotics to Improve Access and Adherence

A new initiative involving a multidisciplinary team is broadening access to psychiatric care by enabling community pharmacists to administer long-acting injectable antipsychotics. This approach aims to address challenges related to patient adherence and improve overall treatment outcomes for individuals requiring these medications.

The collaboration focuses on integrating community pharmacists into the administration process of long-acting injectable antipsychotics, which are often prescribed for patients with conditions such as schizophrenia or bipolar disorder. By empowering pharmacists to deliver these treatments, the program seeks to reduce barriers that patients may face in accessing timely care, including transportation issues or limited availability of specialized healthcare providers. The effort highlights the role of pharmacists as accessible healthcare professionals who can contribute significantly to improving medication adherence and continuity of care within communities.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: June 9, 2025

Related posts:

Biosimilar Manufacturers Face Supply Chain Hurdles Amid Rising Demand, Require Investment in Advanced Tech Generic Drug Makers Face Pressure to Innovate as Personalized Medicine Grows, DrugPatentWatch.com Reports. CDMOs Adopt Advanced Encapsulation Techniques to Address Bioavailability Challenges in Oral Solid Dosage Market Analysis Highlights Role of Pharmacists in Preventing Prescribing Cascades to Reduce Unnecessary Treatments

Author

Mark Chiang